PRESS RELEASE published on 07/23/2024 at 07:30, 6 months 10 days ago Inside Information / News release on accounts, results GenSight Biologics reports cash position of €6.9 million as of June 30, 2024, with potential over 100 vials available upon Q3 resumption of early access program. Company confirms sufficient working capital and successful blending step for LUMEVOQ drug product Working Capital Business Update Cash Position GenSight Biologics LUMEVOQ Drug Product
BRIEF published on 07/11/2024 at 07:35, 6 months 22 days ago GenSight Biologics Launches Newsletter for Retail Investors Financial Updates Gene Therapy Retail Investors LUMEVOQ® Optogenetics
PRESS RELEASE published on 07/11/2024 at 07:30, 6 months 22 days ago Inside Information / Other news releases GenSight Biologics launches a newsletter for retail investors providing updates, news articles, conferences, and financial figures in French, available via subscription on the company's website Subscription Retail Investors Newsletter French GenSight Biologics
BRIEF published on 06/20/2024 at 07:35, 7 months 12 days ago GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates Gene Therapy Operational Update GenSight Biologics Financial Negotiation
PRESS RELEASE published on 06/20/2024 at 07:30, 7 months 12 days ago Inside Information / Other news releases GenSight Biologics renegotiates financial obligations and provides operational updates, with successful capital increases enhancing short-term flexibility Financial Obligations Operational Updates GenSight Biologics Capital Increases Gene Therapies
BRIEF published on 06/04/2024 at 07:35, 7 months 28 days ago GenSight Biologics to Present at Key Medical Conferences in 2024 Gene Therapy GenSight Biologics Medical Conferences 2024 LUMEVOQ® LHON
PRESS RELEASE published on 06/04/2024 at 07:30, 7 months 28 days ago Inside Information / Other news releases GenSight Biologics to present at key medical and stakeholder meetings, including 16th Meeting of the EUNOS. Papers on LUMEVOQ® for LHON to be showcased Gene Therapy GenSight Biologics Medical Conferences LUMEVOQ Retinal Neurodegenerative Diseases
BRIEF published on 06/03/2024 at 07:35, 7 months 29 days ago GenSight Biologics Welcomes William Monteith to the Board of Directors Board Of Directors Nomination GenSight Biologics William Monteith Gene Therapies
BRIEF published on 05/23/2024 at 11:40, 8 months 10 days ago Crossing thresholds for GENSIGHT BIOLOGICS SA Actions Crossing Thresholds GenSight Biologics Armistice Capital Subscription Warrants
BRIEF published on 05/07/2024 at 19:34, 8 months 25 days ago GenSight Biologics Announces Availability of Prospectus for New Shares Listing on Euronext Paris Euronext Paris Capital Increase Gene Therapy Prospectus GenSight Biologics
Published on 02/01/2025 at 00:51, 1 day 16 hours ago Alaska Energy Metals Announces At-the-Market Offering of up to $10 Million
Published on 01/31/2025 at 23:55, 1 day 17 hours ago AGM Renovations Expands Workforce Amid Ontario’s Booming Home Improvement Industry
Published on 01/31/2025 at 23:00, 1 day 18 hours ago CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2024 Results, Thursday, February 20, 2025, at 7:30 a.m. ET
Published on 01/31/2025 at 23:00, 1 day 18 hours ago Metalore Announces Appointments of CFO and Directors
Published on 02/02/2025 at 16:25, 37 minutes ago Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 02/01/2025 at 21:33, 19 hours 29 minutes ago EQS-Adhoc: Dr. Ing. h.c. F. Porsche AG: Possible changes in the Executive Board
Published on 01/31/2025 at 19:00, 1 day 22 hours ago CMUV Bancorp Announces 2024 4th Quarter Financial Results
Published on 01/31/2025 at 18:58, 1 day 22 hours ago EQS-Adhoc: PIERER Mobility AG: Sale of shares in MV Agusta
Published on 01/31/2025 at 17:49, 1 day 23 hours ago EQS-Adhoc: Mynaric extends maturity of three existing bridge loans until February 7, 2025 and expects additional bridge loan, restructuring loan and application for StaRUG proceedings
Published on 01/31/2025 at 18:02, 1 day 23 hours ago Imerys-31-01-2025-information-share-capital-and-voting-rights-as-of-31-December-2024
Published on 01/31/2025 at 14:19, 2 days 2 hours ago OVHcloud announces the success of its refinancing, marked by the success of its inaugural bond issue and the implementation of the first EU Taxonomy-aligned Green Loan by a European cloud player
Published on 01/31/2025 at 08:00, 2 days 9 hours ago AMA: Revenues for the 4th quarter and the full year 2024
Published on 01/30/2025 at 18:00, 2 days 23 hours ago GUILLEMOT CORPORATION: FULL-YEAR 2024 CONSOLIDATED TURNOVER UP 5%
